scPharmaceuticals (NASDAQ:SCPH) Price Target Cut to $12.00 by Analysts at Craig Hallum

scPharmaceuticals (NASDAQ:SCPH) had its target price cut by Craig Hallum from $16.00 to $12.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price target would suggest a potential upside of 252.94% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Stock Performance

SCPH traded down $0.51 during trading on Thursday, reaching $3.40. 2,845,444 shares of the company’s stock were exchanged, compared to its average volume of 259,083. The company has a market capitalization of $170.10 million, a P/E ratio of -2.16 and a beta of 0.15. The company has a quick ratio of 3.66, a current ratio of 4.84 and a debt-to-equity ratio of 4.32. The business has a 50 day moving average price of $4.53 and a 200 day moving average price of $4.50. scPharmaceuticals has a fifty-two week low of $3.24 and a fifty-two week high of $6.71.

scPharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). The business had revenue of $8.05 million for the quarter, compared to analysts’ expectations of $8.04 million. scPharmaceuticals had a negative net margin of 252.18% and a negative return on equity of 201.84%. As a group, analysts predict that scPharmaceuticals will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of scPharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its stake in shares of scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in scPharmaceuticals in the 3rd quarter valued at $57,000. MetLife Investment Management LLC lifted its position in shares of scPharmaceuticals by 135.0% during the 3rd quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after acquiring an additional 9,752 shares during the period. Virtu Financial LLC bought a new position in shares of scPharmaceuticals in the first quarter worth $90,000. Finally, Balanced Rock Investment Advisors LLC raised its stake in scPharmaceuticals by 10.3% in the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock valued at $275,000 after purchasing an additional 5,882 shares in the last quarter. 89.52% of the stock is currently owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.